ArticleAdvances in laboratory medicine2025
The role of the clinical laboratory in the study of mesalazine-induced nephrolithiasis and crystalluria.
Article in Advances in laboratory medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The development of urinary lithiasis is a relatively frequent complication in patients with inflammatory bowel disease (IBD). A multiplicity of factors - including medication - may induce the formation of renal stones and cause complications of variable severity. Case presentation: We report a six-case series of patients with IBD treated with mesalazine who developed renoureteral colic. Spontaneous stone expulsion occurred in three patients, with infrared spectroscopy (IRS) confirming a composition of 100 % mesalazine. In the other three cases, the presence of crystalluria was confirmed in urine sediment during the renal colic. In two of these patients, IRS analysis of dried urine sediment confirmed a mesalazine composition. Conclusions: The scarce literature available on the association between the use of mesalazine and increased risk of lithiasis fails to provide frequency data. Only a previous case on mesalazine crystalluria had been reported in the literature so far, probably due to the difficulty detecting this complication. This case series emphasizes the role of urine sediment analysis in identifying crystalluria and preventing major complications during the follow-up of patients receiving mesalazine therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.